Agitation

5
Pipeline Programs
3
Companies
15
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
4
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
QUETIAPINE FUMARATEApproved
quetiapine
Unknown Company
oral2017
U
SEROQUELApproved
quetiapine
Unknown Company
oral1997
U
SEROQUEL XRApproved
quetiapine
Unknown Company
oral2007

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
QuetiapinePhase 41 trial
Active Trials
NCT00457366Completed72Est. May 2009
Abbott
AbbottABBOTT PARK, IL
1 program
1
Depakote ERPhase 35 trials
Active Trials
NCT00334347Completed5Est. Sep 2007
NCT00315900Terminated20Est. Feb 2008
NCT00211250Completed20Est. Sep 2006
+2 more trials
Teva
TevaIsrael - Petach Tikva
1 program
Naturalistic Adasuve Clinical Trial StudyN/A1 trial
Active Trials
NCT02877108Unknown100Est. Apr 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottDepakote ER
AstraZenecaQuetiapine
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
AbbottDepakote ER
TevaNaturalistic Adasuve Clinical Trial Study
AbbottDepakote ER
AbbottDepakote ER

Clinical Trials (15)

Total enrollment: 1,867 patients across 15 trials

A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR

Start: Jun 2006Est. completion: Sep 20075 patients
Phase 4Completed

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

Start: May 2006Est. completion: May 200972 patients
Phase 4Completed

Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER

Start: Jul 2005Est. completion: Sep 200620 patients
Phase 4Completed

Depakote ER in Bipolar Depression

Start: Jan 2004Est. completion: Jan 200928 patients
Phase 4Completed

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

Start: May 2006Est. completion: Feb 200820 patients
Phase 3Terminated

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

Start: Feb 2005227 patients
Phase 3Completed

Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine

Start: Feb 2005315 patients
Phase 3Completed

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

Start: Jul 2004114 patients
Phase 3Completed

An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents

Start: Mar 2003150 patients
Phase 3Completed

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

Start: Jan 2003370 patients
Phase 3Completed

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

Start: Jul 2003400 patients
Phase 2Completed

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

Start: Feb 2003Est. completion: Dec 200316 patients
Phase 2Completed
NCT02877108TevaNaturalistic Adasuve Clinical Trial Study

Naturalistic Adasuve Clinical Trial Study

Start: Apr 2016Est. completion: Apr 2017100 patients
N/AUnknown

An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.

Start: Jul 2003Est. completion: Dec 200615 patients
N/ACompleted

Depakote ER in Borderline Personality Disorder

Start: Mar 2003Est. completion: Sep 200515 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space